{"id":140338,"title":"Archived 46: Summary of NACI statement of October 21, 2022: Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-18","captureTimestamp":"2025-04-18T14:13:47.624000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-pfizer-biontech-comirnaty-3-mcg-covid-19-vaccine-children-6-months-4-years/summary-october-21-2022.html?wbdisable=true","snippet":"Archived 46: Summary of NACI statement of October 21, 2022: Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age - Canada.ca Skip to main content Skip to \"About government\" We have archived this page and will not…","rawSnapshotUrl":"/api/snapshots/raw/140338","browseUrl":"https://replay.healtharchive.ca/job-1/20250418141347/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-pfizer-biontech-comirnaty-3-mcg-covid-19-vaccine-children-6-months-4-years/summary-october-21-2022.html?wbdisable=true#ha_snapshot=140338","mimeType":"text/html","statusCode":200}